Alimera Sciences (Alimera Sciences) Short Interest

View and export this data going back to 2010. Start your Free Trial

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alimera Sciences Short Interest Distribution

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Short Interest falls into.

Alimera Sciences (Alimera Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Executives

Margaret Pax	director	6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko	director	C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont	director	51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers	other: Chairman Emeritus	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan	director	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman	10 percent owner	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076